All Activity

Positive site, where did u come up with the information on this posting? I'm pleased I discovered it though, ill be checking back soon to find out what additional posts you include. Live Chat Poker88 Asia

“I think that sample fraud should be a death sentence for a licensee. Right now, it’s a $15,000 slap on the wrist.” By Christopher Osher, ProPublica and Evan Wyloge, The Denver Gazette This story was originally published by ProPublica. Colorado marijuana manufacturers would no longer be allowed to choose which product samples they send for mandatory lab testing under a new regulatory proposal discussed at a policy forum on Friday. Instead, the state’s Marijuana Enforcement Division may require independent labs or outside vendors to collect product samples for the testing that’s required before companies can sell their products to ensure they’re free of contaminants. The change would address a long-standing complaint from some marijuana manufacturers that bad actors are cheating the system. They say some companies are selecting samples that can pass tests while sending products to dispensaries that might be contaminated with chemical solvents, fungus or pesticides. A Denver Gazette and ProPublica investigation last month showed that the system for testing marijuana products relies on an honor code that’s open to manipulation. In 2024 alone, Colorado officials found two dozen cases in which companies had violated testing rules, often by submitting samples that were different from what the companies sold in stores or by using unauthorized chemical treatments, according to a review of enforcement actions by the news outlets. The state’s rules on selecting samples require what gets turned over to a lab to be representative of what marijuana companies actually deliver to dispensaries for sale to consumers. “Sample adulteration is a common violation,” Kyle Lambert, deputy director of the division, said during the policy forum. “This is something that we have an interest in more comprehensively addressing based on what we see out there.” Colorado officials have long prided themselves on creating the nation’s first regulated recreational marijuana market, but the news outlets found that the state has fallen behind as other states have adopted more robust regulations. The Denver Gazette and ProPublica highlighted how a popular brand of vapes contaminated with a toxic chemical ended up at marijuana dispensaries. In that case and others, manufacturers were found by regulators to be swapping marijuana distillate, the liquid that goes in vapes, for products chemically converted from much cheaper hemp, which is prohibited in Colorado. The company, Ware Hause, surrendered its marijuana manufacturing license. Its owner declined to comment on Tuesday. The Marijuana Enforcement Division first disclosed it is considering a new sampling system in January. The state’s move marks a shift: Last year, the state fought a lawsuit by a marijuana cultivator aimed at forcing the division to overhaul its testing rules. The suit, brought by Mammoth Farms, also pushed for the division to bar manufacturers from selecting product samples for testing. The division’s lawyers said in a court filing that such a revision would be “impracticable.” A Denver judge dismissed the lawsuit on technical grounds in May, stating that the company should have first petitioned regulators for rule changes. After the dismissal, Mammoth Farms sought rule changes with the Marijuana Enforcement Division. The division agreed to begin requiring more chemical testing this summer but did not adopt a proposal to overhaul how samples are collected. Dominique Mendiola, the senior director of the division, said in a statement that the move to consider changes stemmed from concerns raised by marijuana companies last year. “The division has committed to further researching this topic and leading the facilitation of this dialogue with stakeholders in order to analyze the details and operability of what it would take to implement recommendations to shift to third-party test batch collection requirements,” she said. Twenty-six states and the District of Columbia require lab personnel to collect samples to ensure manufacturers don’t cherry-pick products for testing while holding back contaminated products. Over the next few months, the state will hold discussions with testing labs, marijuana cultivators and manufacturers and industry experts to fashion a formal proposal, Lambert said. He added that he expects the division will take up specific policy recommendations this summer. State officials want to gauge the cost, Lambert said, and make sure they develop effective regulations. The state is also considering who would collect the samples—licensed lab personnel or third-party samplers the state would credential. Kareem Kassem, a director at SC Labs, which has a testing lab in Colorado, said during the forum that all sampling should be done under video surveillance and that vehicles that transport samples should be equipped with GPS monitoring. Other industry representatives noted that changing testing regulations could be expensive and that those costs would be passed on to consumers. They also stressed that other states had marijuana testing scandals even when lab personnel collected samples. Stephen Cobb, co-owner of the marijuana manufacturer Concentrate Brands, pointed to sample collection scandals in California and said the problem was only fixed after regulators stepped in. “We can solve sample fraud,” Cobb said, “but only if there is a massive investment in regulatory oversight on that. Otherwise, it just kind of passes the buck.” The Marijuana Enforcement Division said costs and budgeting issues would be part of the discussions. Still, Justin Singer, the CEO of Denver-based cannabis firm Ripple, applauded the division’s move. “I think that sample fraud should be a death sentence for a licensee,” Singer said during the policy forum. “Right now, it’s a $15,000 slap on the wrist.” He has tracked the division’s enforcement actions and provided The Denver Gazette and ProPublica a spreadsheet and links to those cases. Ripple’s analysis shows that, from the start of 2023 until now, half of the state’s 135 final enforcement actions against marijuana companies involved issues with self-sampling and testing. Singer is also pushing a legislative overhaul to the state’s marijuana testing regimen that would transfer testing oversight to the Colorado Department of Public Health and Environment and create a program where state regulators would randomly test products from dispensaries to ensure they aren’t contaminated. “I hope we all can agree that if we’re not giving consumers as an industry what they think they are buying, then we’re destroying our own industry from within,” Singer said. “Sample fraud and testing fraud is a cancer on our industry. It is a cancer on the businesses that are trying to do good work. It is a cancer on the labs that are trying to be honest.” This article was produced for ProPublica’s Local Reporting Network in partnership with The Denver Gazette. Sign up for Dispatches to get stories in your inbox every week. The post Colorado Officials Weigh Changes To How Marijuana Is Sampled For Testing To Help Avoid Fraud appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks For sharing this Superb article.I use this Article to show my assignment in college.it is useful For me Great Work. situs toto 4d

Nice to be visiting your blog again, it has been months for me. Well this article that i've been waited for so long. I need this article to complete my assignment in the college, and it has same topic with your article. Thanks, great share. paito sgp 4d

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. slot gacor

A key House committee chairman has unveiled the latest version of a large-scale agriculture bill—with provisions his office says will reduce “regulatory burdens for producers of industrial hemp.” The proposed 2026 Farm Bill released on Friday by House Agriculture Committee Chairman Glenn Thompson (R-PA) would maintain the industrial hemp program at a time when the cannabinoid industry finds itself threatened by a pending recriminalization of most consumable cannabinoid products under separate legislation President Donald Trump signed into law last year. But for farmers growing hemp for industrial purposes such as fiber and grain, the latest iteration of the Farm Bill is being pitched as a source of industry relief, with policies allowing the U.S. Department of Agriculture (USDA), as well as states and tribes, to “reduce or eliminate testing requirements and background checks for producers,” for example. Those provisions are modeled after the standalone Industrial Hemp Act, bipartisan legislation introduced in the 118th Congress aimed at bolstering the hemp market that evolved after the crop and its derivatives were federally legalized in 2018 during Trump’s first term in office. Under the new 2026 Farm Bill, USDA would also face a mandate to “establish a process by which laboratories can be accredited for the purposes of testing hemp,” a section-by-section summary says. As it currently stands, only labs accredited by the Drug Enforcement Administration (DEA) are able to test hemp yields for compliance purposes, which has historically created a bottleneck given limited resources. “A new farm bill is long overdue, and the Farm, Food, and National Security Act of 2026 is an important step forward in providing certainty to our farmers, ranchers, and rural communities,” Thompson said of the overall legislation in a press release on Friday. “This bill provides modern policies for modern challenges and is shaped by years of listening to the needs of farmers, ranchers, and rural Americans,” he said. “The farm bill affects our entire country, regardless of whether you live on a farm, and I look forward to seeing my colleagues in Congress work together to get this critical legislation across the finish line.” His panel is set to begin considering the bill on February 23. While the text of the legislation has just been publicly released, Democratic leadership has already taken issue with the proposal as drafted. “Our review of the legislative text is ongoing,” Rep. Angie Craig (D-MN), ranking member of the committee, said. “Based on what I know, the Republican farm bill fails to meet the moment facing farmers and working people.” “Farmers need Congress to act swiftly to end inflationary tariffs, stabilize trade relationships, expand domestic market opportunities like year-round E15 and help lower input costs. The Republican majority instead chose to ignore Democratic priorities and focus on pushing a shell of a farm bill with poison pills that complicates if not derails chances of getting anything done,” she said. “I strongly urge my Republican colleagues to drop the political charade and work with House Democrats on a truly bipartisan bill to address the very real problems farm country is experiencing right now—before it’s too late.” Again, regardless of how the proposed revisions to industrial hemp policy play out, a more pressing concern for the main economic driver of the cannabis market—that is, the farmers, manufacturers and processors of consumable cannabinoid products such as CBD—is not addressed in this latest Farm Bill. Under spending legislation the president signed, cannabinoid products containing even trace amounts of THC would be prohibited once again, which stakeholders say would effectively upend the already struggling marketplace. Since 2018, cannabis products have been considered legal hemp if they contain less than 0.3 percent delta-9 THC on a dry weight basis. However, the law that is set to take effect in November specifies that the weight would apply to total THC—including delta-8 and other isomers. It would also include “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).” The new definition of legal hemp would additionally ban “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or not capable of being naturally produced by it. Legal hemp products would be limited to a per-container total of 0.4 milligrams of total THC or any other cannabinoids with similar effects. A bill titled the Hemp Enforcement, Modernization, and Protection (HEMP) Act represents a potential alternative to the outright THC ban that was included in the spending bill Trump signed, affirmatively allowing the sale of consumable hemp products to adults 21 and older. That includes edibles, beverages and inhalable items. If the legislation is enacted, there would be various regulatory restrictions for the market. For example, packaging couldn’t appeal to youth and would need to be tamper-proof. It would also need to list all cannabinoids present and include QR code linking to a certificate of analysis. Hemp product makers would be prohibited from adding substances like alcohol, caffeine, tobacco, nicotine, melatonin or others “with effects that could interact with cannabinoids or enhance or alter their effects.” There would also be manufacturing and testing requirements, and hemp businesses would need to register their facilities. Additionally, there are provisions mandating the establishment of a total cannabinoid cap on hemp products. The U.S. Department of Health and Human Services (HHS) would be charged with proposing cannabinoid limits within 60 days of enactment. Meanwhile, alcohol retailers recently came together to encourage Congress to delay the enactment of the law Trump signed to federally recriminalize hemp-derived THC beverages and other products. The coalition is calling on lawmakers to pass recently introduced legislation, the Hemp Planting Predictability Act, that would give the hemp industry two more years before a federal ban on THC products would take effect—which stakeholders hope will better position them to negotiate a broader regulatory compromise. House Oversight and Government Reform Committee Chairman James Comer (R-KY), who is cosponsoring the proposal, appeared at a press conference last month alongside farmers who are concerned about the looming federal hemp ban’s impact on their businesses. For what it’s worth, four in five marijuana consumers say they oppose the recriminalization of hemp THC products under the spending bill Trump signed in November. However, it should be noted that that poll was conducted weeks before he issued a cannabis rescheduling order and took steps to protect access to full-spectrum CBD. Meanwhile, a separate recently filed Republican-led congressional bill would stop the implementation of the hemp ban under the enacted appropriations legislation. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Hemp businesses and industry groups have warned about the potential ramifications of the ban, but despite his support for states’ rights for cannabis and a social media post touting the benefits of CBD, Trump signed the underlying spending measure into law without acknowledging the hemp provisions. GOP political operative Roger Stone said recently that Trump was effectively “forced” by Republican lawmakers to sign the spending bill with the hemp THC ban language. However, a White House spokesperson said prior to the bill signing that Trump specifically supported the prohibition language. The Democratic governor of Kentucky said that the hemp industry is an “important” part of the economy that deserves to be regulated at the state level—rather than federally prohibited, as Congress has moved to do. Also, a leading veterans organization is warning congressional leaders that the newly approved blanket ban on consumable hemp products could inadvertently “slam the door shut” on critical research. The post New Farm Bill Released By GOP Committee Chair Aims To Reduce Hemp Industry ‘Regulatory Burdens’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

President Donald Trump has pardoned a former NFL star who was convicted of trafficking 175 pounds of marijuana. As advocates await action on federal marijuana rescheduling—and many people continue to endure the consequences of ongoing cannabis criminalization—Trump granted clemency to five ex-NFL players, including Nate Newton, who helped lead the Dallas Cowboys to three Super Bowl victories in the 1990s. In 2002, however, Newton was arrested in Texas and convicted on federal drug trafficking charges after police discovered $10,000 in his truck and 175 pounds of marijuana in an accompanying vehicle. The president hasn’t publicly discussed the pardon or nature of the offense. “I would like to thank President Trump and all of those that work under him who put this Pardon into effect,” an X account labeled as belonging to Newton posted on Friday. “Thank you Sir for taking time out of your busy day in running this country. Thank you Sincerely and may God bless You.” I would like to thank President Trump and all of those that work under him who put this Pardon into effect. Thank you Sir for taking time out of your busy day in running this country. Thank you Sincerely and may God bless You. Nathaniel Newton Jr. — Nathaniel Newton Jr (@61NateNewton) February 13, 2026 Alice Marie Johnson, who herself received a pardon for a drug offense from Trump during his first term and now serves as the White House pardon czar, also didn’t speak directly to the cannabis conviction that was formally forgiven, but she said on Thursday that “excellence is built on grit, grace, and the courage to rise again,” and “so is our nation.” “Special thanks to [Cowboys owner] Jerry Jones for personally sharing the news with Nate Newton,” she said. “I’m holding Nate’s pardon in my hands today—what a blessed day.” Today, the President granted pardons to five former NFL players—Joe Klecko, Nate Newton, Jamal Lewis, Travis Henry, and the late great Dr. Billy Cannon. As football reminds us, excellence is built on grit, grace, and the courage to rise again. So is our nation. Special thanks… pic.twitter.com/Y4FC5lQwGE — Alice Marie Johnson (@AliceMarieFree) February 13, 2026 Advocates have generally applauded any examples of clemency for people who’ve faced marijuana-related convictions, but such pardons have been relatively rare so far during Trump’s second term—even as he’s pushed the attorney general to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). “I’m encouraged to see President Trump recognize that past cannabis convictions deserve clemency. But there are still people serving lengthy prison terms for less cannabis than Nate Newton had,” Weldon Angelos, founder of the criminal justice non-profit The Weldon Project who received a cannabis-related presidential pardon during Trump’s first term, told Marijuana Moment. “I’m hopeful this momentum continues so that those still incarcerated for cannabis offenses will also receive clemency in the near future.” At the start of his second term, the president fulfilled a campaign promise by commuting the life sentence of Ross Ulbricht, a man who was convicted of running a dark web illicit drug market. The pardons and rescheduling push stand in stark contrast to other administrative drug policy actions, which has also involved military strikes resulting in the deaths of more than 100 people accused of participating in illegal drug trafficking. Newton’s pardon for trafficking 175 pounds of cannabis also comes as people continue to face incarceration or collateral consequences related to federal marijuana convictions for offenses involving lesser amounts of the controlled substance. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Last year, Angelos, the pardon recipient and reform advocate, paid a visit to the White House, discussing future clemency options with Johnson, the pardon czar. Former marijuana prisoners who received clemency from the president during his first term also staged an event outside the White House last April, expressing gratitude for the relief they were given and calling on the new administration to grant the same kind of help to others who are still behind bars for cannabis. In the background of the latest pardons, industry stakeholders and reform advocates are closely monitoring the Justice Department to see what comes of Trump’s December executive order directing Attorney General Pam Bondi to expeditiously complete the cannabis rescheduling process. Separately, Trump recently signed large-scale spending legislation that continues a longstanding policy blocking Washington, D.C. from legalizing recreational cannabis sales. The post Trump Pardons Former NFL Star Convicted Of Trafficking 175 Pounds Of Marijuana appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia senators have advanced an amended bill to legalize recreational marijuana sales in the Commonwealth toward a floor vote while removing new criminal penalties that were recently added to the measure—setting the stage for negotiations between both chambers of the legislature as they work to enact differing versions of the reform. At a hearing before the Senate Finance and Appropriations Committee on Thursday, members passed the legislation from Sen. Lashrecse Aird (D) in a 7-5 vote, along with several amendments that were adopted by the panel’s Resources Subcommittee earlier in the day. This was the last committee stop for the Senate bill, meaning it will next go to the full Senate for consideration at the same time that a House of Delegates version of cannabis sales legalization legislation is set to go to the floor in that chamber. While both are aimed at giving adults a legal means of buying marijuana, the possession and home cultivation of which was legalized in the state in 2021, there are several substantive differences that will need to be resolved before the reform potentially goes to the governor’s desk. In the Senate subcommittee on Thursday, members adopted revisions to increase the conversion fee for medical cannabis operators seeking to serve adult consumers to $15 million and to set an overall tax rate of 17 percent for cannabis products. The new revisions to the Senate bill also propose to make the Cannabis Control Authority a division of the Alcoholic Beverage Control Authority, forming a combined agency that would be called the Alcoholic Beverage and Cannabis Control Authority. Additional changes add provisions to the bill regarding cannabis business banking, a prohibition on internet sales, product registration, packaging, background checks and the license application period, according to a summary delivered by Aird and committee staff. The version of the bill that advanced on Thursday also removes new penalties that were previously added to the bill by the Senate Court of Justice Committee. The latest action came amid pressure from a coalition of advocacy groups that recently sent a letter to senators imploring them to reverse course on those penalty amendments, saying they undermined the “intent” of the legislation and the “will of the people” by adding criminal penalties for certain cannabis-related activity. The amendments at issue included penalties for consumers who buy from unlicensed sources, the recriminalization of cannabis possession by people under 21 and making sales a class 1 misdemeanor for a first offense and a crime punishable by mandatory jail time for a second offense. As revised by the prior panel, the bill would have also raised the penalty for unlicensed cultivation to a felony punishable by up to five years in jail and made it a felony to transport with intent to distribute cannabis across state lines. A separate Senate marijuana sales legalization bill, sponsored by Senate President Pro Tempore Louise Lucas (D), was rolled into Aird’s legislation on Thursday. Despite some key differences, both chambers’ commercial sales bills largely align with recommendations released in December by the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market. Since legalizing cannabis possession and home cultivation in 2021, Virginia lawmakers have worked to establish a commercial marijuana market—only to have those efforts consistently stalled under former Gov. Glenn Youngkin (R), who twice vetoed measures to enact it that were sent to his desk by the legislature. Here are the key details of the Virginia marijuana sales legalization legislation, SB 542 and HB 642: Adults would be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. The House bill sets the state date for legal sales as November 1, 2026, while the Senate measure would allow them to begin on January 1, 2027. The Senate bill would set an excise tax on cannabis products of 12.875 percent, in addition to a 1.125 percent state sales tax and a mandatory 3 percent local tax. The House measure would apply an excise tax of 6 percent as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set a local tax of up to 3.5 percent. Under the House bill, the Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, while the Senate legislation tasks that to a new combined Alcoholic Beverage and Cannabis Control Authority. Tax revenue would be split between the costs of administering and enforcing the state’s marijuana system, a new Cannabis Equity Reinvestment Fund, pre-kindergarten programs, substance use disorder prevention and treatment programs and public health programs such as awareness campaigns designed to prevent drug-impaired driving and discourage underage consumption. Local governments could not opt out of allowing marijuana businesses to operate in their area. Delivery services would be allowed. Serving sizes would be capped at 10 milligrams THC, with no more than 100 mg THC per package. Existing medical cannabis operators could enter the adult-use market if they pay a licensing conversion fee that is set at $15 million in the Senate bill and $10 million in the House measure. Cannabis businesses would have to establish labor peace agreements with workers. A legislative commission would be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. It would also investigate the possibility of the Virginia Alcoholic Beverage Control Authority becoming involved in marijuana regulations and enforcement. Newly sworn-in Gov. Abigail Spanberger (D) supports legalizing adult-use marijuana sales. Meanwhile, House and Senate lawmakers are also advancing separate legislation to provide resentencing relief for people with prior marijuana convictions. The legislation would create a process by which people who are incarcerated or on community supervision for certain felony offenses involving the possession, manufacture, selling or distribution of marijuana could receive an automatic hearing to consider modification of their sentences. The bill applies to people whose convictions or adjudications are for conduct that occurred prior to July 1, 2021, when a state law legalizing personal possession and home cultivation of marijuana went into effect. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the Virginia House on Tuesday approved a bill to protect the rights of parents who use marijuana in compliance with state law. Separately, the Virginia Department of Labor and Industry recently published a new outlining workplace protections for cannabis consumers. Photo courtesy of Chris Wallis // Side Pocket Images. The post Virginia Marijuana Sales Legalization Bill Moves To Senate Floor Vote, Teeing Up Negotiations With House appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Colorado senators have advanced a bill to allow terminally ill patients to use medical marijuana in healthcare facilities such as hospitals. The Senate Health & Human Services Committee on Thursday unanimously approved the legislation from Sen. Kyle Mullica (D) in a 9-0 vote, with amendments. It’s one of the latest examples of a state legislature moving to adopt what’s known as “Ryan’s law,” named after a young cannabis patient in California who passed away. As revised by the panel, the proposal allows health facilities to permit patients who are terminally ill and registered in the state’s medical marijuana program to use cannabis, with certain restrictions. Under SB 26-007, health facilities would be permitted to develop guidelines for the use, storage and administration of medical marijuana. While the measure initially would have mandated that such facilities allow cannabis use, it was revised to simply allow them to set such guidelines. Mullica, the sponsor, said at the committee hearing on Thursday that “this bill was brought to me, really, from a patient’s perspective—and really trying to make sure that, when we have terminally ill patients in the hospital, that we try to make sure that they’re comfortable and making sure that we have a continuation of care.” “I think we still are moving the ball forward here, but also trying to address concerns that we heard from providers and from our hospitals, while still allowing for the conversation to happen of what it looks like for these terminally ill patients to be able to access medication they’ve been using to try to help with the issues they have—to try to keep them comfortable and to try to have that comfort that I think we would all hope that our family members going through a terminally ill disease can can have,” he said. “That’s what we’re attempting here in Senate Bill 7.” The Colorado Department of Public Health and Environment (CDPHE) would be prohibited from requiring compliance with the policy as a condition of obtaining or renewing a license or certification under the bill. Health facilities would be allowed to suspend the policy change if they risked enforcement action by a federal agency. “In FY 2026-27, workload in the Health Facilities and Emergency Medical Services Division in CDPHE will minimally increase to conduct outreach and education to licensed health care facilities regarding medical marijuana use,” a fiscal impact analysis says. “The department may also require legal services, provided by the Department of Law, related to rulemaking and implementation. This workload can be accomplished within existing appropriations.” Other amendments adopted in committee would add additional compliance language, clarify that health facilities wouldn’t be required to store or dispense medical cannabis and limit legal liability for health institutions that permit medical marijuana use. Multiple state legislatures have pursued similar Ryan’s law reforms this session. For example, a bill to allow terminally ill patients in Washington State to use medical cannabis in healthcare facilities such as hospitals, nursing homes and hospices was approved by the House of Representatives on Tuesday. The Virginia Senate passed a measure this week to provide legal protections for hospital workers to facilitate the use of medical marijuana for patients with terminal illnesses in their facilities, so long as cannabis is federally rescheduled. Last week, the Mississippi House of Representatives similarly advanced legislation to allow terminally ill patients to access medical marijuana in health facilities. California and a handful of other states already have laws allowing terminally ill patients to use medical cannabis in healthcare facilities. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Back in Colorado, the state saw over $1 billion in marijuana sales—a milestone the governor touted in December. Gov. Jared Polis (D) also said last week that his state should not have joined a lawsuit supporting the federal ban on gun ownership by people who use marijuana that’s now before the U.S. Supreme Court—and he personally opposes the state attorney general’s “legal position on this.” The post Colorado Senators Advance Bill To Allow Medical Marijuana Use By Terminally Ill Patients In Health Facilities Such As Hospitals appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

As cannabis industry stakeholders await action on a marijuana rescheduling proposal, the Centers for Medicare & Medicaid Services (CMS) has finalized a rule to provide federal health insurance coverage for CBD, according to an executive with a hemp company that’s been collaborating with the agency on the initiative. President Donald Trump signed an executive order in December that directed the attorney general to quickly complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act. While that component of the order made national headlines, another part of the administration’s cannabis plan announced on the same day concerned cannabidiol coverage through Medicare. Mehmet Oz, administrator of CMS, spoke about the initiative at the signing ceremony for the order, crediting Trump and U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for “pushing for change” and “relentlessly” pursuing an agenda rooted in a “deep passion for research.” The plan has been to create a pilot program enabling eligible patients to access hemp-derived cannabidiol that’d be covered under federal health insurance plans, projected to launch by April, according to Oz. Jared Stanley, co-founder of the cannabis company Charlotte’s Web, said on a webinar with other group of cannabis industry stakeholders this week that the rulemaking for CBD coverage that’s being spearheaded by the CMS Innovation Center was internally finalized about two weeks ago. “This pilot will help the [Food and Drug Administration, or FDA] move from uncertainty into a practical framework with clear dosing, risk mitigation and clear manufacturing label expectations that end up rewarding the responsible companies and, in the end, protect and serve the consumer,” he said. Stanley specifically said regulations for the CBD pilot program “were finalized two weeks ago, and we’re hoping and expecting an announcement from the regulatory authorities at some time coming if it’s launching in April.” “As far as the population, it was important to note that it was stated in the briefing that this is starting in a pilot, but expecting to expand beyond just the pilot,” he said. “So that’s multiple indications that we expect to see. And we’re very excited. It has amazing potential.” Asked about the status of the rulemaking, a CMS spokesperson directed Marijuana Moment to a webpage with an FAQ that describes the integration of hemp into a Beneficiary Engagement Incentive (BEI) program under the agency’s Long-term Enhanced ACO Design (LEAD) Model. “The Substance Access BEI gives model participants the option of consulting with their patients about the possible use of eligible hemp products,” the CMS page says. “The implementation of this BEI and any related dispensing would be funded entirely at the participant’s expense; CMS would not cover the cost of such products. Further, CMS will have strict program integrity safeguards to ensure that these incentives do not result in program or patient abuse.” “The Substance Access BEI is only available to participants in states where the eligible hemp products are considered legal,” it says. While the broader rules on the CBD Medicare pilot program haven’t been publicized yet, CMS’s website briefly details how it’s navigating hemp-related issues as part of regulatory models under LEAD, the Accountable Care Organization (ACO) and the Enhancing Oncology Model (EOM). Marijuana Moment reached out to Charolette’s Web for more details about the apparent finalization of CMS’s CBD rules, but representatives were not immediately available. Oz, the CMS administrator, explained in December that the policy change will “allow millions of Americans on Medicare to become eligible to receive CBD as early as April of next year—and at no charge if their doctors recommend them.” He added that Medicare Advantage insurers CMS has contacted are “also agreeing to consider CBD to be used for the 34 million Americans that they cover.” One outstanding question concerns coverage eligibility. As described by the administrator in December, it would affect those 65 and older who qualify for Medicare, but the specific qualifying conditions weren’t detailed. There were repeated mentions of chronic pain, specifically related to cancer, but it’s possible the CBD eligibility criteria includes additional conditions. At the signing ceremony, Oz also gave kudos to Howard Kessler, founder of The Commonwealth Project, which produced a video about the benefits of cannabidiol for seniors that Trump shared on Truth Social last year and who apparently has pressed the president to enact reform to expand cannabis access. While CMS implemented an earlier final rule last April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency is now revising that policy. CMS had already announced certain changes as part of a rulemaking process that was unveiled late last year, affecting “marketing and communications, drug coverage, enrollment processes, special needs plans, and other programmatic areas” for insurance programs it oversees. One of those changes dealt with cannabidiol coverage. The rule as proposed would amend regulations, which currently state that any “cannabis products” cannot be covered. The policy would prevent coverage for only “cannabis products that are illegal under applicable state or federal law, including the Federal Food, Drug, and Cosmetic Act.” Since hemp and its derivatives like CBD are federally legal, the change suggests patients in states where such products are legal could make valid insurance claims to pay for the alternative treatment option, as long as the product is also federally legal. Meanwhile, following the White House announcement in December, Oz spoke with NewsNation about the policy change, responding to a question about how the broader marijuana rescheduling decision squares with the Trump administration’s aggressive efforts to stymie the flow of other illicit drugs, particularly fentanyl. “We think they fit hand in hand,” he said. “This is really about researching—specifically CBD, which is hemp-derived endocannabinoids [sic]—are actually worthy of Americans using them,” he said. “It’s hard to do some of this work, especially with medical marijuana. And this is not about legalization of marijuana.” “There is no legalization language at all,” he added. “It’s about rescheduling this class of product so that it can be researched more readily.” The idea that marijuana has no medical value, as its currently defined as a Schedule I drug, is “just patently wrong for marijuana,” he said, noting that the Food and Drug Administration (FDA) has approved certain cannabis-based drugs for conditions such as epilepsy “that work quite nicely.” “That belief that it should be Schedule I is just an incorrect place to put it,” he said. “Schedule III seemed to make sense to the president. He argued that it allows us to do the research more readily.” “We’re finding a way to allow Medicare beneficiaries to get access to some of these products. And so, within Medicare, we have the ability, for the first time ever—and we delivered on this promise to the president today—to allow doctors to recommend hemp-derived CBD for patients who have cancer, for example, and have a lot of pain from that.” The administrator said surveys show a majority of seniors who take CBD for pain management find it beneficial, and the White House wants to “make it easier for patients to access this” and allow them to access the cannabinoid at “no charge” through the federal health insurance program. In recent years, Oz has encouraged audiences to be open to therapeutic cannabis and advocated for sweeping policy changes around the drug. “We ought to completely change our policy on marijuana. It absolutely works,” he said in a 2020 interview, calling cannabis “one of the most underused tools in America.” In 2024, he wrote in a syndicated health column that there’s evidence cannabinoids can curb seizures, alleviate nausea associated with cancer treatment and potentially help manage pain—especially in older people. Oz also said in 2020 that he believes that, particularly for seniors, marijuana for pain represents a “safer solution than, for example, narcotics in many cases.” Photo courtesy of Kimzy Nanney. The post Federal Agency Finalized Rule For CBD Medicare Coverage Pilot Program Weeks Ago, Key Hemp Stakeholder Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

El tema de los pagos siempre es delicado, pero con pin-up https://pin-up-ec.org/ he tenido muy buenas experiencias. He solicitado varios retiros de mis ganancias y el proceso ha sido transparente y seguro. Usan métodos que son familiares para nosotros en Ecuador, facilitando mucho las transacciones en dólares. Es importante completar la verificación de identidad lo antes posible para no tener retrasos en el primer retiro. Una vez hecho eso, los siguientes pagos suelen ser mucho más rápidos. Se nota que es una empresa seria que respeta el dinero de sus usuarios. Nunca he tenido problemas de saldo retenido injustificadamente ni comisiones ocultas extrañas. La claridad en las finanzas es un punto fuerte que me hace seguir eligiendo esta plataforma sobre otras.

Maryland senators have taken up a bill to extend a psychedelics task force through the end of 2027 to develop updated recommendations on expanding therapeutic access to the novel drugs and potentially creating a regulatory framework for broader legalization. The Senate Finance Committee considered the legislation from Sen. Brian Feldman (D) at a hearing on Thursday. A Home companion version sponsored by Del. Pam Guzzone (D) was separately taken up by the Health Committee on Tuesday. The proposals are aimed at building upon a current law that created the Maryland Task Force on Responsible Use of Natural Psychedelic Substances. That panel released an initial final report to state lawmakers last year, with recommendations for the phased implementation of a wide range of reforms to provide legal therapeutic access to substances such as psilocybin. “The mission was to study the use of natural psychedelic substances and make recommendations regarding changes to state law, policy and practices to create a Maryland natural psychedelic substance access program and to make recommendations to transition from the criminalization of these substances,” Feldman said at Thursday’s hearing. “This is a really hard-working group of individuals.” Members of the task force have already advised that it was ultimately recommending a “multi-pathway framework for safe, broad, and equitable access to natural psychedelic substances, with an initial focus on psilocybin.” The psychedelics task force was formed following Gov. Wes Moore’s (D) signing of a pair of bills into law in 2024. The 17-person body, overseen by the Maryland Cannabis Administration (MCA), was charged with studying how to ensure “broad, equitable and affordable access to psychedelic substances” in the state. SB 336 and HB 427 would continue that work, maintaining the panel through December 31, 2027. In the interim, the task force would be required to submit an updated report to legislators with additional findings and recommendations by October 31 of this year. Andrew Coop, chair of the task force, told the committee that psychedelic substances “affect mood and perception” and “have been used for millennia in spiritual ceremonies.” “While unique risks do exist, clinical trials show efficacy for treatment-resistant depression, cancer-related anxiety, PTSD, traumatic brain injury, chronic pain, headache and more,” he said. “The additional time we’re asking for the next report is to develop those ideas so we can put draft regulations in place so that this can be a benefit to all citizens.” Shanetha Marable-Lewis, an Army veteran and member of the task force, said that “Maryland has been a pioneer in psychedelic science since the 1950s, leading groundbreaking research that has shaped global understanding of these compounds.” “This history and tradition uniquely well-positions us to create responsible resident-centered, evidence-based policy that leads to national access models rather than simply reacting to or replicating them,” she said. “The task force does not support delaying state action pending future federal approval. This is due to the fact that, despite federal restrictions and the absence of [Food and Drug Administration-approved] options, clinical and public interest in psychedelic-assisted therapy is surging nationwide.” Beyond the extended timeline for the task force to study and develop the report, the current law would not change under the legislation. The multi-step regulatory framework that members recommended last year “involves phased implementation of complementary elements from medical/therapeutic use and supervised adult use, to deprioritization, and to commercial sales,” the report said. “This model broadly and inclusively serves the needs of Maryland’s diverse population while enabling unified safety standards, accountability, and viable economic pathways for small businesses.” The first phase of the plan would be to create an advisory board to establish safety parameters, data monitoring, practice guidelines, licensing protections, public education campaigns, training for facilitators, law enforcement and testing facilities, as well as “immediate restorative justice measures,” the report states. Under phase two, the state would implement “deprioritization measures” to mitigate the harms of criminalization, provide for supervised medical and adult-use consumption facilities, allow personal cultivation for “permitted individuals” and promote research processes. Finally, phase three would be contingent on the “demonstrated safety outcomes and provider confidence” based on the prior steps. Should those factors be satisfied, the last phase would lead to a commercial sales program for adults “who maintain an active license to use natural psychedelic substances,” coupled with an evaluation of the state’s “readiness for expanding to additional natural psychedelic substances.” “Safety and oversight measures ensure responsible and gradual expansion of access while maintaining capacity to identify and respond to emerging issues swiftly,” the report said. “This approach plans for long-term learning and improvement: starting small, utilizing built-in evaluation and accountability mechanisms from the outset, gathering real-world data, and committing to an iterative approach to policymaking.” Notably, the task force said it did not support “delaying state action pending future federal [Food and Drug Administration] approval.” “The Task Force recognizes that implementing such a comprehensive framework requires careful sequencing and coordination, with particular attention to scope of practice issues that may significantly affect the viability and safety of different pathways. However, the order of implementation must carefully consider professional regulatory frameworks and safety concerns raised by medical organizations and health care providers. The Task Force’s recommendation for simultaneous implementation of multiple pathways does not mean that all components must activate on the exact same day, but rather that Maryland should avoid the sequential approach seen in other jurisdictions where implementing one pathway causes others to ‘languish,’and/or bolster black and gray markets.” Rather, the task force said, the multi-phase approach to psychedelics reform “establishes foundational systems that support all pathways equally, followed by a coordinated launch of medical, supervised adult use, and deprioritization pathways, with commercial sales following once product safety systems are operational.” Members also said that the model envisioned could be used by other states to develop their own laws that “adapt to their own circumstances and values.”At this point, the task force is only looking at psilocybin, mescaline and DMT. While the legislature empowered members to investigate potential regulations for other psychedelic substances, they decided to take a more conservative approach in their initial work. As originally introduced, the House version of the task force legislation contained more prescriptive requirements to explore and issue recommendations on aspects of psychedelics policy such as “systems to support statewide online sales of natural psychedelic substances with home delivery” and “testing and packaging requirements for products containing natural psychedelic substances with clear and accurate labeling of potency.” That language was ultimately removed, however. The task force legislation advanced about two years after a different law took effect creating a state fund to provide “cost-free” access to psychedelics like psilocybin, MDMA and ketamine for military veterans suffering from PTSD and traumatic brain injury. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last week Maryland lawmakers took up a bill to protect the gun rights of medical marijuana patients in the state. Members of the House Judiciary Committee discussed the legislation from Del. Robin Grammer (R) last Wednesday. The delegate has sponsored multiple versions of the cannabis and gun rights measure over recent sessions, but they have not yet advanced to enactment. Meanwhile, a Republican congressional lawmaker representing Maryland who has built a reputation as one of the staunchest opponents of marijuana reform on Capitol Hill—and whose record includes ensuring that Washington, D.C. officials are blocked from legalizing recreational cannabis sales—may be at risk of being unseated in November due to redistricting in his state. Image courtesy of CostaPPR. The post Maryland Senators Weigh Bill To Extend Psychedelics Task Force Through 2027 appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“True stability requires comprehensive federal legislation that creates a national medical cannabis framework to recognize cannabis-based therapies as part of modern healthcare.” By Steph Sherer, Americans for Safe Access Last week, the House Appropriations Committee declared victory, announcing: “More than 95 percent of the federal government is funded through full-year FY2026 appropriations—delivering stability, certainty, and results for the American people.” But for millions of medical cannabis patients, that claim rings hollow. Instead of delivering stability, the Fiscal Year 2026 budget reinforces a troubling reality: Congress continues to manage medical cannabis through temporary fixes and political compromises—rather than building a healthcare system patients can rely on. Widespread misinformation about the true impact of President Donald Trump’s December 2025 executive order is compounding uncertainty for patients. While the order does emphasize research and coordination, it does not resolve core access barriers, create new patient protections or replace the need for congressional action. So, while a significant development, it is not necessarily the breakthrough it has been portrayed as. As a result, uncertainty is growing across the patient community. Those who rely on hemp-derived medicines, veterans dependent on Department of Veterans Affairs (VA) healthcare and people living in newly authorized or underdeveloped state programs are particularly vulnerable. For many, the future of their care feels more precarious today than it did a year ago. A Letdown To End The Shutdown In November 2025, Congress passed a massive stopgap spending bill to end a federal shutdown. It combined several budget measures into H.R. 5371, The Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, and pushed the rest into a short-term funding extension. Congress Delivered 2 Major Blows in November with the Passage of H.R. 5371 Under the Agriculture portion of the spending bill, Congress permanently redefined hemp and hemp-derived cannabinoid products. These changes were long overdue and designed to close what lawmakers called the “hemp loophole,” which had allowed intoxicating products to spread nationwide with little oversight. However, these provisions, set to take effect in November, will also remove most full-spectrum products from lawful hemp commerce. From a regulatory standpoint, the new language brings clarity. From a patient standpoint, it will bring disruption. Millions of Americans rely on full-spectrum hemp products to manage seizures, cancer symptoms, chronic pain, PTSD and neurological disorders—often because their states lack functional medical cannabis programs. Unless Congress intervenes, millions of patients will lose one of their few affordable treatment options. For people already marginalized by the healthcare system, this is not a technical regulatory adjustment. It is a looming healthcare crisis. In response, Americans for Safe Access recently released a policy briefing, Protecting Patient Access: A Compassionate Response to Changing Federal Hemp Laws, calling on states to create transitional pathways for patients. But state action can only go so far in the absence of federal leadership. Veterans Left Behind—Again The second blow came in the VA portion of the legislation. For more than fifteen years, advocates have sought to allow Veterans Health Administration providers to recommend medical cannabis and assist veterans with state program enrollment. Language to do so appeared in both House and Senate bills but did not make it into the final legislation signed into law. Under current VA policy, providers remain prohibited from recommending, referring, or assisting veterans with medical cannabis—even in states where it is legal. Veterans coping with chronic pain, traumatic brain injury, and PTSD are left to navigate fragmented systems without clinical support. Once again, those who served our country are denied access to care that could improve their quality of life. Another Year Of Protections For Some To be clear, the FY2026 budget was not a total loss for patients. Medical cannabis protections were preserved in the Commerce, Justice, Science (CJS) and other related agencies appropriations. Advocates successfully removed provisions that would have blocked rescheduling and another that would have reopened the door to federal interference in state programs. These protections remain temporary and require annual renewal. Since 2014, the Medical Marijuana CJS Amendment has protected state medical cannabis programs, patients and healthcare providers from federal prosecution, arrest, asset forfeiture and harassment. The provision has received bipartisan support for more than a decade and was meant to serve as a critical safeguard while Congress works toward comprehensive medical cannabis legislation. Unfortunately, Nebraska was excluded from the longstanding medical cannabis amendment that bars federal agencies from interfering with state programs—despite voters decisively approving medical cannabis in 2024. Advocates had hoped that Nebraska’s exclusion was a technical oversight, as this marks the first time since the amendment’s initial passage in 2014 that a newly authorized medical cannabis state was not added. More concerning is that Sen Deb Fischer (R-NE), a member of the Senate Appropriations Committee, did not offer an amendment to correct this omission. Nebraska’s struggle for safe access has been particularly contentious. In March 2025, Sen. Pete Ricketts (R-NE), the former governor of Nebraska, weighed in on the state legislature’s implementation efforts in an op-ed in the Omaha World-Herald, co-authored with the state’s attorney general, warning lawmakers not to allow the program to move forward—an intervention widely viewed as an overreach of his federal position. Meanwhile, Congress declined to fund meaningful medical cannabis oversight at the Department of Health and Human Services (HHS). Despite Trump’s executive order emphasizing research and coordination, no dedicated resources were provided. Implementation is left to existing agency budgets and shifting priorities. The order directs HHS to explore real-world evidence and standards of care. But without funding or statutory authority, these efforts will remain limited. Regulatory Changes Can’t Fix A Broken System Uncertainty Extends Beyond Appropriations In January, the Centers for Medicare & Medicaid Services closed public comments on proposed rules that would allow non-cannabinoid hemp products and certain cannabis products legal under state or federal law to be reimbursed under the Special Supplemental Benefits for the Chronically Ill (SSBCI) program. While a modest step forward, it offers little practical relief for many patients. Individuals in hospice, assisted living and long-term care facilities are still often prohibited from accessing these therapies until federal law changes—leaving some of the nation’s most vulnerable patients caught between policy reform and legal reality. This week, the Food and Drug Administration faced a deadline (February 10) under the new hemp law to publish a list of all cannabinoids produced by the plant, clarify THC-related compounds, and define container limits. But this technical exercise will not prevent the loss of access. The agency is implementing a statute. It cannot rewrite it Meanwhile, Trump’s executive order also directed the Department of Justice to revive the stalled cannabis rescheduling process. But rescheduling alone will not create a medical program, protect patients or integrate cannabis into healthcare. Without comprehensive legislation, these regulatory efforts—however well-intentioned—amount to administrative adjustments layered onto a fundamentally broken system. Stability Requires Legislation For more than a decade, Congress has relied on short-term protections, budget riders and partial reforms to manage medical cannabis. That approach has reached its limits. Patients cannot build treatment plans around temporary funding provisions. Healthcare systems cannot integrate therapies governed by annual political negotiations. Veterans cannot depend on executive discretion. Families cannot plan their care in the face of regulatory uncertainty. True stability requires comprehensive federal legislation that creates a national medical cannabis framework to recognize cannabis-based therapies as part of modern healthcare, empowering HHS to oversee safety, standards,and integration. Bottom line, patients need protection regardless of where they live, what system they rely on or which political party controls Congress. Patients need a system that treats their medicine as a lifeline, not an afterthought. Steph Sherer is the founder and executive director of Americans for Safe Access. The organization has published a congressional briefing on medical cannabis issues. The post Federal Budget Leaves Medical Cannabis Patients More Uncertain Than Ever (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

NY gov signs marijuana biz zoning fix; VA cannabis consumers’ parental rights; FL medical marijuana expansion; CO cannabis revenue outpaces alcohol Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Before you dig into today’s cannabis news, I wanted you to know you can keep this resource free and published daily by subscribing to Marijuana Moment on Patreon. We’re a small independent publication diving deep into the cannabis world and rely on readers like you to keep going. Join us at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Food and Drug Administration Commissioner Marty Makary said the Trump administration is “very serious” about advancing medical cannabis access through rescheduling—but that it is also concerned about “side effects” like psychosis and “problems with learning and judgment.” New York Gov. Kathy Hochul (D) signed legislation to allow more than 150 marijuana businesses to remain open after regulators’ error in interpreting zoning rules threatened to force them to close. The Virginia House of Delegates passed a bill to protect the parental rights of marijuana consumers by making it so a child would not be considered abused or neglected because of a parent or guardian’s cannabis use alone. The Florida Senate Health Policy Committee approved a bill to expand medical cannabis access by making patient registrations last longer, increasing smokable marijuana supply limits and slashing registration fees for military veterans. A new report from Colorado Legislative Council staff shows that marijuana revenue is declining as other states legalize and due to the availability of intoxicating hemp products—but that it still outpaces the state’s alcohol and cigarette tax haul. / FEDERAL The U.S. Court of Appeals for the Eleventh Circuit upheld the conviction of a man for possessing a firearm as a felon due to his record for possession of marijuana with intent to distribute. The Senate bill to create a pathway for patients to access Schedule I drugs got one new cosponsor for a total of two. The House bill to federally regulate hemp products got two new cosponsors for a total of five. The House bill to direct the Department of Veterans Affairs to conduct clinical trials on psychedelics got one new cosponsor for a total of two. / STATES Florida’s agriculture commissioner cheered a court ruling upholding total THC limits for hemp products. Separately, the health care administration secretary acknowledged that state officials used opioid settlement funds to campaign against a marijuana legalization ballot initiative in 2024. The Oklahoma House Committee on Alcohol, Tobacco and Controlled Substances approved bills to extend a medical cannabis business license moratorium and limit the number of cultivation licenses. An Illinois senator filed legislation to amend various cannabis rules. A Washington State representative discussed her legislation to legalize marijuana home cultivation. A Minnesota judge overturned regulators’ restrictions on shipping hemp products directly to consumers. California regulators are moving to update cannabis pesticide testing rules. Maryland’s top marijuana regulator said she hopes that as many as 60 new dispensaries will open by the fall. Massachusetts cannabis regulators clashed over punishments for a testing lab. New Jersey marijuana regulators spoke about efforts to crack down on unlicensed marijuana sales. Missouri generated $255 million in marijuana tax revenue in 2025. Virginia regulators posted a reminder about rules for sharing and gifting marijuana ahead of Valentine’s Day. The Rhode Island Cannabis Control Commission will meet on Friday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Colorado Springs, Colorado is using marijuana revenue to fund a firefighter training academy. / INTERNATIONAL Germany’s Federal Court of Justice is considering restrictions on medical cannabis advertising. / SCIENCE & HEALTH A case study “highlights the potential benefits of combining cannabis oil with physiotherapy for managing post-stroke dystonic tremor and” post-stroke thalamic pain. A study found “evidence for antinociceptive effects of CBD in a model of incisional wound-related pain.” / ADVOCACY, OPINION & ANALYSIS The UK Green Party is set to vote on a motion supporting drug legalization next month. / BUSINESS Aurora Cannabis Inc. officials will ring the Nasdaq closing bell on Wednesday. / CULTURE Whoopi Goldberg promoted her cannabis-infused sex lube brand at a conference. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post FDA head discusses cannabis benefits & concerns (Newsletter: February 13, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Tax revenue from marijuana sales has gradually decreased in Colorado over the past five years as more states have enacted legalization and as intoxicating hemp products have grown in popularity, state officials say in a new report. Nonetheless, cannabis is still bringing in more tax dollars compared to alcohol or cigarettes. In a memorandum from the Colorado legislature’s nonpartisan Legislative Council, staff sought to answer “common questions about how revenue from the marijuana industry fits into Colorado’s state budget.” That includes the $231.1 million in cannabis revenue the state collected in the 2024-25 fiscal year. Adult-use marijuana is taxed at three levels in Colorado: A 15 percent excise tax, 15 percent special sales tax and 2.9 percent state general sales tax. As one of the first states to legalize marijuana for recreational use, Colorado saw revenue from those sales grow “consistently for the first eight years of legalization, peaking at $424.4 million FY 2020-21.” Following that, however, “revenue fell for the first time in FY 2021-22, and has declined each year since,” the Legislative Council said. “Marijuana tax revenue fell to $231.1 million in FY 2024-25, 45.5 percent below its FY 2020-21 peak.” Notably, the memo says that the declining tax revenue from marijuana in more recent years is “has largely been due to low prices and falling demand as other states across the country legalize marijuana, and alternatives like intoxicating hemp become more widely available.” Early on Gov. Jared Polis (D), a longtime champion of cannabis reform, was perceptive to the potential economic impact of the spread of legalization, poking fun about how he hoped states like Texas would continue to stall on the issue so Colorado could continue to reap the marijuana tourism dollars. Texas might still remain a prohibitionist state, but with cannabis now legal for adult use in nearly half of the states in the U.S., that broader shift has evidently contributed to the revenue decline. But the new report also says the rise of intoxicating hemp products is diverting tax dollars. Whether that changes when a federal ban on such products takes effect in November is yet to be seen. Even with the spread of state-level legalization and increased consumer demand in the intoxicating hemp market, however, Legislative Council released data showing that marijuana remains a more potent revenue generator compared to other vices, including alcohol and cigarettes. In the 2024-25 fiscal year, marijuana sales generated more tax revenue than alcohol ($54.3 million), tobacco products ($68.2 million), nicotine products ($91.6 million) and cigarettes ($213.9 million). Via LCS. To that point, surveys have consistently found that Americans are increasingly choosing marijuana and cannabis-infused beverages over alcohol and cigarettes. Meanwhile, in 2025 alone, Colorado saw over $1 billion in marijuana sales—a milestone the governor touted in December. And while Legislative Council attributed part of the decline in cannabis sales to intoxicating hemp product sales, Polis also recently said the pending federal ban will “stifle growth and innovation” in the market. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the governor said last week that his state should not have joined a lawsuit supporting the federal ban on gun ownership by people who use marijuana that’s now before the U.S. Supreme Court—and he personally opposes the state attorney general’s “legal position on this.” The post Colorado Marijuana Revenue Is Declining As Other States Legalize, But It Still Outpaces Alcohol Taxes, Report Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The governor of New York has signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. The bills, passed by the House and Senate and signed by Gov. Kathy Hochul (D) on Wednesday, also grandfather in more than 150 existing retailers whose locations were retroactively found to be out of compliance with zoning requirements that created a buffer between cannabis dispensaries and schools and churches. Last year, New York regulators notified the licensed retailers that they were mistakenly granted approval for their locations because the way distance was measured placed them closer to schools or places of worship than was permitted under the law. While the marijuana law as enacted restricted zoning based on distance between a retailer and a school or church property line, in multiple cases the distance was being improperly assessed based on distance from main entryway to main entryway rather than by the edge of property lines. Once the mistake was identified, the state notified affected businesses that they would either have to close or relocate. But amid litigation and industry pressure, the governor pledged to work with lawmakers to address the issue legislatively. Now a door-to-door distance measuring policy has been codified under the measures from Assemblymember Stefani Zinerman (D) and Sen. Liz Krueger (D). The new law specifies that cannabis retailers cannot be located on the same street and within 500 feet of a school, nor can they be located on the same street and within 200 feet of a house of worship. Measurements to establish that distance, the newly enacted law states, must be “taken in straight lines from the center of the nearest entrance of the premises sought to be licensed to the center of the nearest entrance of such school or house of worship.” A justification memo attached to the legislation says it will “codify the ‘door-to-door’ policy that had been in place at [the Office of Cannabis Management, or OCM] prior to July 28, 2025, and would grandfather in licenses granted as well as certain applications previously submitted under that standard.” “If the school, house of worship or premises sought to be licensed is set back from a public thoroughfare, the walkway or stairs leading to any such door shall be deemed an entrance; and the measurement shall be taken to the center of the walkway or stairs at the point where it meets the building line or public thoroughfare,” the bills, A10140 and S9155, state. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last month New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. All told, retail cannabis sales in New York have exceeded $2.5 billion since the passage of recreational legalization, including $1.6 billion that was generated last year alone as of November. Also, licensed storefronts nearly doubled from 261 in 2024 to 556 in 2025. The OCM annual report also notes that Hochul signed legislation into law that expands the state’s medical cannabis program by improving patient access and “updating the program framework to better meet patient needs statewide.” The legislation the governor signed also grants reciprocity to out-of-state residents, streamlines the patient certification process and allows adults 18 and older to grow their own cannabis plants for therapeutic use. Separately, given confusion within the marketplace about timelines for provisional licenses, regulators said they will be extending the renewal deadline for conditional adult-use until December 31, 2026. “This extension provides licensees additional time to secure viable locations and move toward full licensure,” OCM said. “It will also apply to any provisional licenses issued between September 9, 2025, and December 30, 2025, ensuring clarity and consistency for all provisional license holders.” Last July, meanwhile, New York officials announced the first round of grants under a $5 million program to help retail marijuana businesses owned by justice-involved people cover startup costs. The post New York Governor Signs Bills To Fix Marijuana Business Zoning Issue That Threatened Closure Of Over 150 Dispensaries appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The head of the Food and Drug Administration (FDA) says that while the Trump administration is taking the potential harms of marijuana use among youth “very seriously,” it’s also important to preserve access to cannabis for medical purposes—and that’s part of the thinking behind the push to federally reschedule it. In an interview on Fox Business on Wednesday, FDA Commissioner Marty Makary was asked about a recent New York Times editorial published that called for safeguards around marijuana, citing contested data on the relationship between cannabis use and health issues such as psychosis. “First of all, we’ve seen a dramatic increase in teens vaping with THC…in the four years prior to us coming into office. So we’re taking this very seriously, and we’re trying to understand this field of science with better research,” he said. “The marijuana today is not the marijuana of hippies. It’s 10 to 20 times stronger, and new research is showing that its effect on the developing adolescent mind is different than in an adult.” “It can result in psychosis diagnoses later in life. So we are taking this very seriously, and it is a controlled substance in the Trump administration, and so that’s the state of affairs,” Makary said, adding that there are other “side effects” associated with marijuana such as cannabis hyperemesis syndrome. “I think if you simply talk about the dangers of marijuana in kids in terms of risk, remember, risk appeals to many kids, so we have to talk about what it does to their ability to compete in a track-and-field match, and what it does to their day-to-day sort of vitality,” the FDA commissioner said. “It creates fatigue, and it creates problems with learning and judgment, so we have to talk about that.” While the interview made rounds on social media, drawing criticism from industry stakeholders, there was less focus on other comments Makary made concerning the Trump administration’s efforts to ensure that patients are able to access marijuana for medical uses. “We are also in the Trump administration very serious about making sure that the medicinal purposes—that is, the indications where people find benefit in medical conditions, for example, with chronic terminal cancer—is advanced,” he said. “And so we’ve taken action to change the scheduling from Schedule I to Schedule III” under the Controlled Substances Act (CSA). President Donald Trump issued an executive order in December order Attorney General Pam Bondi to expeditiously complete the rescheduling process, which was initiated under the Biden administration, but there haven’t been any recent updates on the Justice Department’s progress in seeing through that directive. Meanwhile, last month, the Drug Enforcement Administration (DEA) said the cannabis rescheduling appeal process “remains pending” despite Trump’s executive order. A recent Congressional Research Service (CRS) report discussed how DOJ could, in theory, reject the president’s directive or delay the process by restarting the scientific review into marijuana. Bondi separately missed a congressionally mandated deadline last month to issue guidelines for easing barriers to research on Schedule I substances such as marijuana and psychedelics. Last year, the FDA commissioner said exploring the therapeutic potential of psychedelics such as psilocybin and ibogaine is a “top priority” for the Trump administration, especially when it comes to helping military veterans grapple with trauma from being sent to fight “unnecessary wars.” Meanwhile, asked about the widespread availability of intoxicating cannabinoid products, such as delta-8 THC, Makary warned last year that the use of cannabinoids can lead to cardiac problems and psychosis. The post FDA Head Says Marijuana Has ‘Benefit In Medical Conditions,’ But Trump Administration Also Concerned About ‘Side Effects’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Virginia House of Delegates has approved a bill to protect the rights of parents who use marijuana in compliance with state law. The legislation from Del. Nadarius Clark (D) is consistent with a measure he sponsored last session that advanced through the legislature, only to be vetoed by then-Gov. Glenn Youngkin (R). The latest version passed the House in a 62-37 vote on Tuesday. Under the proposal, possession of use of cannabis by a parent or guardian on its own “shall not serve as a basis to deem a child abused or neglected unless other facts establish that such possession or consumption causes or creates a risk of physical or mental injury to the child.” “A person’s legal possession or consumption of substances authorized under [the state’s marijuana law] alone shall not serve as a basis to restrict custody or visitation unless other facts establish that such possession or consumption is not in the best interest of the child,” the text of the bill, HB 942, states. When the bill was on the floor for second reading on Monday, Clark said that the measure “fully preserves judicial discretion requiring a court to act when a child is in danger, but grounding those decisions in individualized evidence-based findings instead of presumptions tied to lawful conduct.” Youngkin claimed in his veto message last year that the prior measure introduced “unnecessary complications and risks exposing children to harm.” “The bill disregards clear evidence linking substance use to child endangerment, particularly in the wake of increased incidents of children ingesting cannabis-infused substances following the legalization of marijuana,” he argued. “By broadly prohibiting courts from considering parental marijuana use in custody and visitation determinations, [the bill] risks prioritizing drug use over the health and well being of children.” The then-governor also vetoed an even earlier version of the bill in 2024. While current Gov. Abigail Spanberger (D) hasn’t specifically weighed in on the parental rights legislation, she is generally more supportive of marijuana reform than her predecessor and backs legalizing recreational cannabis sales, which Youngkin also vetoed. Meanwhile, the Virginia Senate this week approved a bill to provide legal protections for hospital workers to facilitate the use of medical marijuana for patients with terminal illnesses in their facilities, so long as cannabis is federally rescheduled. lawmakers are also considering more robust reforms to the state’s marijuana laws, including proposals to legalize recreational cannabis sales. The Senate Courts of Justice Committee passed an amended version of that bill last week, drawing criticism from advocates over changes that would impose new penalties on certain cannabis-related activities such as underage possession and unlicensed cultivation of marijuana that could carry the threat of jail time. A coalition of reform groups has since sent a letter to the Senate Finance Committee, where the measure was transmitted, imploring members to roll back those amendments. As approved in committee, the legislation largely aligns with recommendations released in December by the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market. Since legalizing cannabis possession and home cultivation in 2021, Virginia lawmakers have worked to establish a commercial marijuana market—only to have those efforts consistently stalled under former Gov. Glenn Youngkin (R), who twice vetoed measures to enact it that were sent to his desk by the legislature. The Senate version calls for sales to start on January 1, 2027, while the House bill stipulates that adult-use cannabis sales could begin on November 1 of this year. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Another cannabis bill approved by the Senate Courts of Justice Committee last week would mandate that individuals with certain offenses automatically receive resentencing hearings and have their punishments adjusted. A House companion version from Del. Rozia Henson, Jr. (D) also advanced recently. The legislation would create a process by which people who are incarcerated or on community supervision for certain felony offenses involving the possession, manufacture, selling or distribution of marijuana could receive an automatic hearing to consider modification of their sentences. The bill applies to people whose convictions or adjudications are for conduct that occurred prior to July 1, 2021, when a state law legalizing personal possession and home cultivation of marijuana went into effect. Separately, the Virginia Department of Labor and Industry recently published a new outlining workplace protections for cannabis consumers. The post Virginia House Passes Bill To Protect Rights Of Parents Who Use Marijuana appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Florida senators have approved an amended bill to increase the amount of medical marijuana a registered patient can buy and slash the fee for medical cannabis identification cards for military veterans. At a hearing before the Senate Health Policy Committee on Wednesday, members advanced the legislation from Sen. Alexis Calatayud (R) in a vote of 10-1 after adopting a substitute version. Under the proposal as amended, a doctor would be able to recommend up to five 70-day supply limits of cannabis or up to 10 35-day supply limits of smokable marijuana products. Under current law, they can only provide recommendations for a maximum of three 70-day supply limits for non-smokable cannabis and six 35-day supply limits for smokable marijuana. The bill, SB 1032, would further make it so doctors would need to evaluate patients for medical marijuana qualification every 52 weeks, rather than the current statutory requirement of evaluations every 30 weeks. A similar version of medical cannabis legislation was introduced in the House by Rep. Bill Partington (R) in late December. Calatayud’s proposal as amended in committee would additionally reduce the fee for medical cannabis identification cards for honorably discharged veterans to $15—down from the current $75 fee for most qualifying patients. Two House panels have advanced separate standalone legislation from Reps. Susan Valdés (R) and Michelle Salzman (R) that would similarly reduce veterans’ medical marijuana card fee to $15. If enacted into law, the broader Senate bill would take effect on July 1, 2026. Wednesday’s committee vote comes after the Senate Regulated Industries Committee passed separate legislation to ban smoking or vaping marijuana in public places. Rep. Alex Andrade (R) is sponsoring a similar bill to ban public cannabis smoking in the House. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Here’s an overview of other pending Florida marijuana bills: A House lawmaker is sponsoring a bill to legalize recreational marijuana that also aims to break up what he calls “monopolies” in the state’s current medical cannabis program by revising the business licensing structure. Another representative’s bill would protect the parental rights of medical cannabis patients, preventing them from losing custody of their children for using their medicine in accordance with state law. A senator is sponsoring a bill to legalize home cultivation of marijuana for registered medical cannabis patients in the state. Meanwhile, the Florida Supreme Court last week cancelled oral arguments and closed a case concerning a marijuana legalization ballot initiative that was under review at the request of the state attorney general. Attorney General James Uthmeier (R) notified the court on Monday that he was withdrawing his request for a legal review into the cannabis measure because election officials determined the campaign behind it had fallen short of the signature requirements for ballot placement. But while the campaign urged the court to reject the notice of dismissal, contesting the signature count, justices on Wednesday accepted the attorney general’s motion. Smart & Safe Florida has disputed the secretary of state’s signature count, claiming the campaign submitted over 1.4 million petitions—hundreds of thousands more than the 880,062 valid signatures required to go before voters. In a filing with the Supreme Court, Uthmeier said his office was withdrawing its earlier request for a legal review in the constitutionality of the proposed cannabis initiative because the state claims the campaign submitted an insufficient number of signed petitions. The last count, according to the secretary of state’s office, was 783,592 validated signatures. Photo courtesy of Brian Shamblen. The post Florida Senators Approve Bill To Increase Medical Marijuana Supply Limits And Slash Patient Fees For Veterans appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Your blog is too much amazing. I have found with ease what I was looking. Moreover, the content quality is awesome. Thanks for the nudge! 강남도파민 영업시간

I did so have fun with perusing content pieces circulated on this internet site. They've been awesome as well as a considerable amount of effective advice. are you covered by workers' comp at home

VA legal marijuana sales & resentencing; VA & WA cannabis in hospitals; SD anti-marijuana bills defeated; HI legalization stalls; WI decrim Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW A federal judge dismissed marijuana businesses’ lawsuit challenging Customs and Border Protection’s seizures of state-legal cannabis products in New Mexico. The Virginia House Appropriations Committee approved bills to legalize recreational marijuana sales and provide resentencing relief for people with prior cannabis convictions—while the Senate Finance & Appropriations Committee also advanced resentencing legislation. The Virginia Senate passed a bill to allow patients to use medical cannabis in hospitals, and the House Health and Human Services Health Subcommittee advanced similar legislation on medical marijuana access in healthcare facilities. The Washington State House of Representatives passed a bill to allow terminally ill patients to use medical cannabis in healthcare facilities such as hospitals, nursing homes and hospices. The South Dakota Senate Health and Human Services Committee rejected bills that would have repealed the state’s medical cannabis program following federal rescheduling and instituted THC potency limits on medical marijuana products. Hawaii’s House speaker and the chair of the House Judiciary and Hawaiian Affairs Committee say marijuana legalization bills are effectively dead for the 2026 session, upending advocates’ hopes that lawmakers would at least refer the issue to the ballot for voters to decide. Bipartisan Wisconsin lawmakers are circulating a bill to decriminalize marijuana by replacing the threat of jail time for first-time possession of up to 28 grams of cannabis with a $100 fine. Ohioans for Cannabis Choice launched a signature drive to collect more than 248,000 signatures ahead of a March 19 deadline for a referendum to block new marijuana and hemp restrictions from taking effect. The Oregon Senate Early Childhood and Behavioral Health Committee is expected to vote on a bill to ban marijuana edibles containing more than 10 milligrams of THC on Thursday. / FEDERAL National Institute on Drug Abuse Director Nora Volkow coauthored a blog post on how scientists are using a large health dataset to support research, including a study that found that “people who used multiple substances or stimulants tended to report poorer overall health, had more disrupted sleep, and were less physically active, while people who only used cannabis looked similar to non-users on many of these measures.” Rep. Mike Flood (R-NE) tweeted, “The growing use of bioengineered marijuana products is harming millions of Americans. Some scoffed at the idea that marijuana use was linked to deteriorating mental health. But new data is confirming the link between psychotic disorders and marijuana use.” The Senate bill to continue applying the 280E tax penalty on marijuana businesses after rescheduling got one new cosponsor for a total of two. / STATES Missouri’s attorney general filed a lawsuit against a business for allegedly selling unregulated THC products without a license. Nebraska Democratic attorney general candidate Jocelyn Brasher discussed her support for medical cannabis. Florida elections officials posted lower signature counts for a proposed marijuana legalization ballot initiative than were reported by county officials. Arizona regulators announced a recall of marijuana products due to possible contamination with aspergillus. Oklahoma regulators suspended the operations of several medical cannabis businesses over alleged violations. Michigan regulators filed a complaint against a marijuana business over alleged violations. Alabama officials have so far approved five physicians to recommend medical cannabis. California regulators sent updates on various cannabis issues. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Los Angeles, California City Council voted to place a measure on the ballot to enact a tax on unlicensed cannabis businesses. / INTERNATIONAL The European Food Safety Authority set a provisional safe intake level for CBD. / SCIENCE & HEALTH A study found that “THC inhibits S mutans growth and biofilm formation while also reducing bacterial viability, [extracellular polysaccharides] production, and acid production,” suggesting that “THC may reduce the cariogenic capacity of S mutans.” A study found that “licensed mental health clinicians feel comfortable and knowledgeable in working with a client disclosing cannabis use and were neutral when asked about clinical judgments” and that there were “neutral to positive attitudes towards recreational and medical cannabis use in general.” / ADVOCACY, OPINION & ANALYSIS The County Road Association of Michigan filed an amicus brief opposing a lawsuit challenging a new marijuana tax. / BUSINESS UPMC Pinnacle Hospitals reached a settlement with a former employee who sued over allegedly being unlawfully fired after he tested positive for cannabis while using CBD gummies to manage chronic spinal pain. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis businesses’ lawsuit against feds is dismissed (Newsletter: February 12, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

In Cowboy Safari, the wind whistles louder than the bucking beast beneath you—hold tight or taste the dust.

Great roundup — I found a server with excellent lore and RP communities. Immersive storytelling made leveling more enjoyable. Real votes supported the vibrant RP scene. bandar slot gacor Very informative — the server comparison on event rewards was useful. Slot Very useful — the listing of server reseller policies clarified trustworthy partners. Avoiding shady resellers protects both players and server integrity. Real votes flagged reputable servers. olxtoto I really like the idea of full-size customization for latex. The glossy finish makes the apparel stand out. Personalized designs add individuality. Global delivery in 20 days is impressive. olxtoto Great roundup — I found a server with excellent lore and RP communities. Immersive storytelling made leveling more enjoyable. Real votes supported the vibrant RP scene. data warna sgp lotto Very informative — the server comparison on event rewards was useful. pestoto

This is so cool! Reminds me of the randomness of https://omegleweb.io Omegle back in the day. Finding venues sounds like an awesome adventure. I wish I had access to some secret locations! Maybe try reaching out to local event planners or film crews? They often know of interesting spots. Good luck with the scouting!